Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by …

leukemia
fibrosis
flt3 gene
allogeneic hematopoietic stem cell transplant
gilteritinib
  • 0 views
  • 2 annotations
  • 19 Feb, 2024
Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy in breast cancer patients treated with adjuvant trastuzumab.

immunomodulators
anthracycline
angiotensin
immunostimulant
adjuvant
  • 0 views
  • 19 Feb, 2024
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors

However, the fear of hepatic, digestive (colon, esophagus, stomach) or even cardiac toxicities limits its using to the majority of patients because coupled with a conventional scanner it do not allow direct visualization of the lesion.

cancer
liver diseases
hepatitis
skin cancer
metastasis
  • 0 views
  • 19 Feb, 2024
Cardio-Oncology Registry

The objectives are to provide a comprehensive vue of cardoi-oncology, enable to detect early signals of cardiotoxicity and enhance ancillary projetcts aiming at specific populations (e.g., type of cancer) and/or drugs.

cancer
cardiotoxicity
  • 0 views
  • 19 Feb, 2024
Cancer Therapy Effects on the Heart

Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) is commonly given to treat pediatric cancer, and carries a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death.

anthracycline
childhood cancer
diagnostic tests
pediatric
daunorubicin
  • 0 views
  • 19 Feb, 2024